Sugar.fit, a health-tech startup that seeks to manage and reverse Type 2 and Pre-diabetes through a holistic, science-backed, and data-driven digital health experience, has announced its $11 million Series A funding round today. The funding was led by MassMutual Ventures with participation from existing investors including Cure.fit, Tanglin Venture Partners, and Endiya Partners. The fresh capital will be used to expand Sugar.fit’s product offering, launch an offline presence and accelerate research and development in the field of diabetes management, accelerating the brand’s footprint and growth.

Madan Somasundaram, co-founder & CEO of Sugar.fit says, "We are grateful for the trust and support our investors have in us. We are more committed than ever to help people with Type 2 and pre-diabetes manage and reverse their condition. This investment will enable us to further enhance our technology and expand our reach across India, ultimately helping more people take control of their diabetes and improve their health.”

Anvesh Ramineni, Managing Partner at MassMutual Ventures says, "We are thrilled to lead the Series A funding round for Sugar.fit. The team’s approach to diabetes management combines hardware, software, and analytics to deliver a personalized program and drive lasting behavioral change for better health outcomes. We believe Sugar.fit will transform the health of millions while battling the increasing incidence of diabetes in India."

Mukesh Bansal, Founder of Cure.fit says, "We are very proud of the progress Sugar.fit has made in the last two years. This is the best team in this space with the strongest diabetes reversal metrics. We believe Sugar.fit will revolutionize the market and help millions of Indians in reversing the disease."

Founded in 2021, Sugar.fit initially raised $10 million in a seed funding round and has proven exceptional growth. In the last 18 months, the brand has witnessed eightfold growth in paid subscribers and currently serves over 25,000 users on its platform.